ES2325992T3 - Utilizacion de partes o de un extracto de amaranthus blitoides. - Google Patents

Utilizacion de partes o de un extracto de amaranthus blitoides. Download PDF

Info

Publication number: ES2325992T3
Authority: ES; Spain
Prior art keywords: extract; amaranthus blitoides; parts; patients; extracts
Prior art date: 2003-06-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES04739741T

Other languages

English (en)

Spanish (es)

Inventor

Eva-Maria Nedwig

Maria Milovanovic

Jovan Radoijcic

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-24

Filing date

2004-06-09

Publication date

2009-09-28

2003-07-10 Priority claimed from DE10332281A external-priority patent/DE10332281A1/de

2004-06-09 Application filed by Individual filed Critical Individual

2009-09-28 Application granted granted Critical

2009-09-28 Publication of ES2325992T3 publication Critical patent/ES2325992T3/es

2024-06-09 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

240000006273 Amaranthus graecizans Species 0.000 title claims abstract description 26
235000013593 Amaranthus graecizans Nutrition 0.000 title claims abstract description 26
239000000284 extract Substances 0.000 title claims abstract description 26
206010061218 Inflammation Diseases 0.000 claims description 5
239000006286 aqueous extract Substances 0.000 claims description 5
208000014617 hemorrhoid Diseases 0.000 claims description 5
230000004054 inflammatory process Effects 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
239000000825 pharmaceutical preparation Substances 0.000 claims description 5
244000269722 Thea sinensis Species 0.000 claims description 4
210000002307 prostate Anatomy 0.000 claims description 4
210000001635 urinary tract Anatomy 0.000 claims description 4
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
230000001476 alcoholic effect Effects 0.000 claims 1
235000020344 instant tea Nutrition 0.000 claims 1
235000013616 tea Nutrition 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 7
208000027866 inflammatory disease Diseases 0.000 abstract description 3
230000000694 effects Effects 0.000 description 11
230000000202 analgesic effect Effects 0.000 description 5
239000003814 drug Substances 0.000 description 5
230000002048 spasmolytic effect Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
229940120889 dipyrone Drugs 0.000 description 3
229940079593 drug Drugs 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 3
239000002674 ointment Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000589516 Pseudomonas Species 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000003187 abdominal effect Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000008602 contraction Effects 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000008141 laxative Substances 0.000 description 2
208000017497 prostate disease Diseases 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
241000219318 Amaranthus Species 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
241000700198 Cavia Species 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010013082 Discomfort Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
240000008415 Lactuca sativa Species 0.000 description 1
208000019255 Menstrual disease Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010030124 Oedema peripheral Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
241000588770 Proteus mirabilis Species 0.000 description 1
206010037596 Pyelonephritis Diseases 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
206010064921 Urinary tract inflammation Diseases 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000012675 alcoholic extract Substances 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000001741 anti-phlogistic effect Effects 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
230000013872 defecation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
150000002215 flavonoids Chemical class 0.000 description 1
235000002864 food coloring agent Nutrition 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013402 health food Nutrition 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
238000009533 lab test Methods 0.000 description 1
229940125722 laxative agent Drugs 0.000 description 1
230000002475 laxative effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000036407 pain Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000000419 plant extract Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000012045 salad Nutrition 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000004575 stone Substances 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
235000018553 tannin Nutrition 0.000 description 1
239000001648 tannin Substances 0.000 description 1
229920001864 tannin Polymers 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Medical Informatics (AREA)
Botany (AREA)
Alternative & Traditional Medicine (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines Containing Plant Substances (AREA)
Cosmetics (AREA)
Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

ES04739741T 2003-06-24 2004-06-09 Utilizacion de partes o de un extracto de amaranthus blitoides. Expired - Lifetime ES2325992T3 (es)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
DE10329248		2003-06-24
DE10329248		2003-06-24
DE10332281		2003-07-10
DE10332281A DE10332281A1 (de)	2003-06-24	2003-07-10	Verwendung von Teilen oder eines Extrakts von Amaranthus blitoides
US51964103P	2003-11-14	2003-11-14
US519641P		2003-11-14

Publications (1)

Publication Number	Publication Date
ES2325992T3 true ES2325992T3 (es)	2009-09-28

Family

ID=33544856

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES04739741T Expired - Lifetime ES2325992T3 (es)	2003-06-24	2004-06-09	Utilizacion de partes o de un extracto de amaranthus blitoides.

Country Status (5)

Country	Link
EP (1)	EP1641477B1 (de)
AT (1)	ATE428435T1 (de)
DE (1)	DE502004009359D1 (de)
ES (1)	ES2325992T3 (de)
WO (1)	WO2004112812A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120164240A1 (en)	2010-12-22	2012-06-28	Audino David Lawrence	Enriched a. blitoides compositions and uses thereof
KR20150136537A (ko) *	2013-04-02	2015-12-07	에어 프로덕츠 앤드 케미칼스, 인코오포레이티드	퍼스널 케어 제품을 위한 전달 시스템의 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3651733B2 (ja) *	1997-05-29	2005-05-25	御木本製薬株式会社	化粧品用薬剤および薬用化粧品
JP2000143524A (ja) *	1998-11-06	2000-05-23	Ichimaru Pharcos Co Ltd	アマランサス抽出物含有抗炎症剤
IN191020B (de) *	2000-03-28	2003-09-13	Dabur Res Foundation

2004
- 2004-06-09 ES ES04739741T patent/ES2325992T3/es not_active Expired - Lifetime
- 2004-06-09 DE DE502004009359T patent/DE502004009359D1/de not_active Expired - Lifetime
- 2004-06-09 WO PCT/EP2004/006235 patent/WO2004112812A1/de not_active Ceased
- 2004-06-09 EP EP04739741A patent/EP1641477B1/de not_active Expired - Lifetime
- 2004-06-09 AT AT04739741T patent/ATE428435T1/de active

Also Published As

Publication number	Publication date
DE502004009359D1 (de)	2009-05-28
ATE428435T1 (de)	2009-05-15
WO2004112812A1 (de)	2004-12-29
EP1641477B1 (de)	2009-04-15
EP1641477A1 (de)	2006-04-05

Publication	Publication Date	Title
ES2303342T3 (es)	2008-08-01	Agentes antivirales obtenidos de extractos de plantas y su uso para el tratamiento de infecciones viricas.
Ndhlala et al.	2013	Antibacterial, antifungal, and antiviral activities of African medicinal plants
Gardiner	1999	Chamomile (Matricaria recutita, anthemis nobilis)
Roy et al.	2010	Antiulcer and anti-inflammatory activity of aerial parts Enicostemma littorale Blume
ES2462553A1 (es)	2014-05-23	Composición para mejora del bienestar sexual
Walker-Bone	2003	‘Natural remedies’ in the treatment of osteoarthritis
ES2325992T3 (es)	2009-09-28	Utilizacion de partes o de un extracto de amaranthus blitoides.
CN102743663B (zh)	2015-04-08	一种治疗泌尿系感染的中药制剂及其制备方法
CN100446794C (zh)	2008-12-31	一种治疗胃肠道疾病的中药制剂
Aleem et al.	2020	History and Traditional uses of Tiryaq (Theriac): An important formulation in Unani medicine
Kapoor et al.	2013	Illustrated medical pharmacology
Kishanrao et al.	2015	A brief review of research studies conducted on Panchavalkal
ES2394316T3 (es)	2013-01-30	Composiciones farmac�uticas de Carapa Guianensis.
CN103251691B (zh)	2015-03-04	治疗奶牛乳房炎的中药方剂及其提取物和制剂
CN101606930B (zh)	2011-11-09	土槿乙酸及其衍生物在制备免疫抑制剂中的应用
Spiteri	2011	Herbal monographs including herbal medicinal products and food supplements
RU2410096C1 (ru)	2011-01-27	Способ лечения больных псориазом в сочетании с хроническим описторхозом
BRPI1002720B1 (pt)	2020-09-15	Uso de um extrato vegetal
CN119564661B (zh)	2025-09-23	一种具有协同解热镇痛抗炎效果的药物组合物及应用
ES2850152T3 (es)	2021-08-25	Uso de un extracto de withania para el tratamiento de sinucleinopatías alfa
RU2620548C1 (ru)	2017-05-26	Способ профилактики респираторных болезней телят
RU2553308C1 (ru)	2015-06-10	Капли плетнева, обладающие противовирусным и иммуномодулирующим эффектами
Geetha	2020	Combating attention deficit hyperactivity disorder with natural treatment.
Bharadwaj et al.	2013	Experimental evaluation of prophylactic and curative effect of a herbal drug Hemidesmus indicus R. Br. in drug induced ulcers in Wistar albino rats
RU2391995C1 (ru)	2010-06-20	Средство для лечения злокачественных и доброкачественных новообразований различной локализации